Type 1 Diabetes
Pipeline by Development Stage
Drug Modality Breakdown
Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.
Key Trends
- GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
- SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
- Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins
Career Verdict
Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 26% | Launch | Stable | 14.9yr |
| 2 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 13% | Peak | Growing | 12.3yr |
| 3 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 12% | Peak | Growing | 8.5yr |
| 4 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 10% | Peak | Stable | |
| 5 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.3yr |
Drug Class Breakdown
stable, mature franchise
rapid growth, expanding indications
growing, cardio-renal expansion
stable, generics pressure
declining, patent cliff 2027
Career Outlook
GrowingMetabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.
Breaking In
Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.
For Experienced Professionals
Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.
In-Demand Skills
Best For
Hiring Landscape
Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.
Top Hiring Companies
By Department
Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.
On Market (3)
Approved therapies currently available
Competitive Landscape
51 companies ranked by most advanced pipeline stage
+21 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 10,632 patients across 50 trials
Insulin Pump to Multiple Daily Injection Transition Clinical Trial
Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes (FIT)
52 Week Trial of Liraglutide in Type 1 Diabetes
Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study
Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes
Satisfaction of Treatment Among Elderly Patients With Insulin Therapy
Performance Evaluation of Blood Glucose Monitoring Systems
Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial
Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia
Skype for Youth With Poorly Controlled Diabetes
Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)
Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes
Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus
Insulin Analogues and Severe Hypoglycaemia
Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness
Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes
Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings
Rosiglitazone and Insulin in T1DM Adolescents
Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus
D-chiro-Inositol in Overweight Type 1 Diabetes Patients
EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes
New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
US Inhaled Insulin Dose Titration Study
US Inhaled Insulin Therapeutic Choice Questionnaire Study
A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control
Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus
Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose
Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration
Related Jobs in Metabolic Diseases
Clinical Diabetes Specialist- Corpus Christi
Territory Business Leader - Raleigh
Manager, Medical Information
Clinical Diabetes Specialist - Baltimore
Clinical Diabetes Specialist - Seattle
Quality Control Senior Specialist
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.